Multiple ascending dose study of extended-release oral formulation of EV-077.

Trial Profile

Multiple ascending dose study of extended-release oral formulation of EV-077.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2011

At a glance

  • Drugs SER 150 (Primary)
  • Indications Cardiovascular disorders; Thrombosis
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jul 2011 Status changed from recruiting to completed, according to information in an Evolva media release.
    • 16 Dec 2010 New trial record
    • 16 Dec 2010 This study is expected to be completed in the first half of 2011, according to an Evolva media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top